Companhia Siderúrgica Nacional (NYSE:SID) Q4 2025 Earnings call March 12, 2026 10:30 AM ET Company ParticipantsBenjamin Steinbruch - CEOHelena Guerra - Director of ESG and SustainabilityLuis Fernando Martinez - Executive DirectorMarcelo Arazi - Equity Research Associate DirectorMarco Rabello - CFO and Investor Relations OfficerConference Call ParticipantsDaniel Sasson - Equity Research AnalystEnrique Marquez - AnalystNicholas S. - AnalystPedro Melo - Research AnalystRafael Barcellos - Senior Equity Research ...

Summary of Altimmune's Conference Call Company Overview - **Company**: Altimmune - **Key Executives Present**: Jerry Durso (CEO), Christophe Arbet-Engels (CMO), Greg Weaver (CFO) [1][2] Industry and Product Focus - **Industry**: Biotech, specifically focusing on liver diseases such as Metabolic Associated Steatotic Hepatitis (MASH), Alcohol Use Disorder (AUD), and Alcohol-Associated Liver Disease (ALD) - **Key Product**: Pemvidutide, a dual-action drug targeting glucagon and GLP-1 receptors [4][12] Key Highlights and Core Points Clinical Progress - **MASH Trials**: Significant progress in the Phase 2 MASH trial with 24-week and 48-week data showing potential for pemvidutide as a differentiated product in the MASH space [4][5] - **AUD Trials**: Enrollment ahead of schedule with top-line data expected in Q3 2026 [8] - **ALD Trials**: Enrollment expected to complete this year with two main readouts at 24 weeks and 48 weeks [43] Financial Position - **Balance Sheet**: Focus on strengthening the balance sheet through a combination of debt and equity, with discussions ongoing with strategic partners [6] - **Capital Allocation**: Emphasis on ensuring sufficient capital for the Phase 3 trial initiation [6] Differentiation of Pemvidutide - **Mechanism of Action**: Unique one-to-one ratio of glucagon and GLP-1, showing strong effects on fibrosis and MASH resolution [12] - **Tolerability**: Lower discontinuation rates compared to competitors, with a focus on preserving lean mass during weight loss [12][13] - **Data Insights**: Positive 48-week data indicating a clear dose response and strong anti-fibrotic effects [19] Phase 3 Trial Design - **Trial Structure**: Three arms including placebo and two doses (1.8 mg and 2.4 mg), with a focus on good tolerability observed in Phase 2 [22] - **Use of AIM-MASH AI Assist**: A novel tool to reduce variability in histology readings and improve objectivity in trial outcomes [26][29] Regulatory Considerations - **FDA Discussions**: Ongoing discussions with the FDA regarding the use of non-invasive tests (NITs) as endpoints, with current data being captured for potential future discussions [35] Market Potential - **AUD Population**: Estimated 12 million individuals in the AUD category, with a significant unmet need for effective treatments [50] - **Pricing Strategy**: Anticipation of different pricing strategies for MASH and AUD therapies, with a focus on differentiation and value [52][53] Additional Insights - **Enrollment Timelines**: Expectation to complete enrollment for trials within 18-24 months, leveraging strong site relationships and previous trial learnings [38] - **Patient-Reported Outcomes**: Emphasis on capturing both subjective and objective measures of treatment efficacy in AUD trials [40][41] Conclusion - Altimmune is positioned for a significant year ahead with multiple ongoing trials and a focus on innovative treatment approaches for liver diseases, particularly through the development of pemvidutide. The company is actively working on strengthening its financial position and preparing for Phase 3 trials while engaging with regulatory bodies to optimize trial outcomes and market entry strategies.

Summary of MetaVia Conference Call - March 12, 2026 Company Overview - **Company**: MetaVia (NasdaqCM:MTVA) - **Industry**: Life Sciences, specifically focusing on obesity treatment Key Points and Arguments Obesity Market and Product Differentiation - MetaVia's lead asset, DA-1726, is positioned in the obesity market, differentiating itself from existing GLP-1 based drugs by combining GLP-1 and glucagon receptor agonism [2][4] - Current approved obesity drugs primarily target GLP-1 and GLP-1 plus GIP, while DA-1726 aims to balance GLP-1 and glucagon to enhance weight loss and metabolic outcomes [4][5] Scientific Rationale - The combination of GLP-1 and glucagon is believed to increase energy expenditure while maintaining glycemic control, potentially leading to better weight loss outcomes compared to standalone GLP-1 drugs [4][6] - MetaVia has established a 3-to-1 ratio of GLP-1 to glucagon, which has shown promising results in preclinical models, including a 25% increase in food intake while maintaining weight loss [5][7] Clinical Data and Efficacy - In an 8-week Phase I study, DA-1726 demonstrated a 9.1% decrease in body weight, a 3.8-inch reduction in waist circumference, a 0.22 decrease in HbA1c, and a 23.7% decrease in liver stiffness [11][14] - The drug is expected to achieve a weight loss target of 12%-15% in a 16-week study, which would position it favorably against competitors [22] Safety and Tolerability - MetaVia aims to differentiate DA-1726 by minimizing gastrointestinal side effects, which are common in other GLP-1 glucagon drugs [19][31] - The company plans to conduct a two-step titration in the upcoming Phase 3A study to control side effects while maximizing efficacy [20][21] Market Positioning - The focus is on patients with obesity and metabolic conditions, particularly those with non-alcoholic steatohepatitis (NASH) and type 2 diabetes, leveraging the drug's liver benefits [35] - MetaVia's valuation is currently low compared to other obesity drug companies, presenting a potential investment opportunity as new data is expected to be released [41][42] Future Milestones - Upcoming data releases from the Phase 3A study and combination therapy trials are anticipated to provide insights into the drug's efficacy and safety profile [39][40] - The company is also exploring other indications for its small molecule drug, Vanoglipol, which has shown a good safety profile and efficacy in hepatic effects [39] Conclusion - MetaVia is positioned to make significant strides in the obesity treatment market with its innovative approach and promising clinical data, making it a potential investment opportunity as it prepares for upcoming trials and data releases [41][42]

Companhia Siderúrgica Nacional (NYSE:SID) Q4 2025 Earnings call March 12, 2026 10:30 AM ET Speaker8Good afternoon, ladies and gentlemen. At this time, we would like to welcome everyone to CSN's Earnings Conference Call for the fourth quarter 2025 and full year. Today, we have with us the company's executive officers. We would like to inform you that this event is being recorded, and all participants will be in listen-only mode during the company presentation. Ensuing this, we will go on to the question and ...

Financial Data and Key Metrics Changes - In Q4 2025, the company generated revenues of approximately $157 million, consistent with guidance, but decreased due to seasonality and budget exhaustion [10] - Adjusted EBITDA for Q4 was approximately $23 million, the highest quarterly adjusted EBITDA of the year, with an adjusted EBITDA margin of about 14% [10][11] - For the full year, corporate adjusted EBITDA loss was around $26 million, reflecting a structural rightsizing of G&A and a 12% decline in total headcount year-over-year [12] Business Line Data and Key Metrics Changes - Northeast MidCon revenue was essentially flat at $69.6 million, with an adjusted EBITDA margin expansion to 25.3% driven by gas-directed activity [11] - Dry gas revenue in the Northeast MidCon increased 5.3% quarter-over-quarter and 44% year-over-year [8][11] - Rockies revenue declined to $46.3 million, down approximately 9% sequentially, primarily due to weather and budget exhaustion [11] - Southwest revenue decreased about 10% to $50.9 million, linked to budget exhaustion and reduced oil-directed activity, but adjusted EBITDA increased to $6.8 million [11] Market Data and Key Metrics Changes - The company noted a 6% increase in rig count across the Northeast MidCon segment quarter-over-quarter [24] - The overall market is expected to see a gradual improvement, particularly in gas-directed basins, with a forecast for Q1 2026 revenue of $145 million-$150 million, down approximately 3% from Q1 2025 [20][18] Company Strategy and Development Direction - The company continues to focus on higher margin, technically differentiated work while maintaining cost discipline and strategically deploying capital [6] - The capital program is predominantly maintenance-oriented, with gross capital expenditures expected to be approximately $40 million for 2026, down from $49 million in 2025 [12][20] - The company is positioned to benefit from industry consolidation and capacity rationalization, with smaller competitors exiting the market [20] Management's Comments on Operating Environment and Future Outlook - Management expressed a constructive but measured outlook for 2026, anticipating Q1 to be the low point of the year due to seasonal factors [18] - The company is monitoring the impact of the Middle East conflict on market conditions, noting that historical trends show a 60-90 day lag in activity changes following commodity price movements [44][48] - The internal budget for 2026 contemplates flat to slightly up revenue compared to 2025, with improvements expected in the second half of the year [19] Other Important Information - The company ended 2025 with total debt of $258.3 million and available liquidity of approximately $56 million [13] - A proactive amendment to the indenture was made to provide covenant relief, allowing for a net leverage ratio of 4.5x through March 31, 2027 [16] Q&A Session Summary Question: Strength in Northeast MidCon - Management noted a 6% increase in rig count in the Northeast MidCon segment and attributed the strength to diverse geographic exposure and robust gas-directed activity [24][26] Question: Revenue Decline in Southwest - The revenue decline in the Southwest was attributed to budget exhaustion and completion programs tailing off, with some assets being realigned to other regions [32][33] Question: CapEx and Cash Flow Outlook - The company is targeting gross capital spending of $40 million for 2026, reflecting a prudent approach given the current market conditions [34][35] Question: PIK Option and Covenant Relief - Management explained that the PIK option provides flexibility in cash management, and the covenant relief was a proactive measure to ensure adequate cushion for future periods [36][37] Question: Impact of Middle East Conflict - Management indicated that the impact of the Middle East conflict is uncertain, but historical trends suggest a lag in activity changes following commodity price movements [44][48] Question: Simul-frac Adoption - The company has seen slower adoption of simul-frac in the MidCon compared to other basins, with approximately 25%-30% of operations utilizing this method [58][60] Question: U.S. Coiled Tubing Market - Management acknowledged attrition in the coiled tubing market, with some players exiting, but noted that the market is currently balanced without significant shortages [63][66]

Financial Data and Key Metrics Changes - For the quarter ending December 31, 2025, the company generated distributable earnings of $0.27 per share, impacted by a loan foreclosure which reduced earnings by approximately $0.03 per share [8][16] - For the full year ended December 31, 2025, net interest income was $21.6 million, with distributable earnings of $15.2 million or $1.19 per share [16] - The company ended the fourth quarter with total assets of $310.2 million and total shareholder equity of $182 million, with a book value of $13.56 per share [18] Business Line Data and Key Metrics Changes - The company closed on $368 million of loans during the fiscal year, with $247 million committed and $224 million funded by the company [7] - In the fourth quarter of 2025, the company closed on $56 million of commitments, including loans for industrial and retail properties [12] - As of February 27, 2026, the portfolio, excluding the Thompson Hotels, consisted of $442.1 million of current commitments and $337 million of principal outstanding across 16 loans [17] Market Data and Key Metrics Changes - The company observed a bifurcation in the commercial real estate lending market, with lenders focused on multifamily and industrial assets experiencing tight spreads [10] - The company noted that the market volatility has created opportunities for transitional deals, despite recent uncertainty due to rising rates [21][23] Company Strategy and Development Direction - The company remains focused on providing loans for transitional real estate business plans, primarily in the Southern United States, with a strategy centered on residential loans [5] - The company aims to partner with top-tier sponsors for high-quality real estate projects, emphasizing structured solutions for complex deals [11][13] Management's Comments on Operating Environment and Future Outlook - Management indicated that the current market volatility presents both challenges and opportunities, particularly in identifying transitional deals [21][23] - The company expressed confidence in its ability to capitalize on attractive opportunities despite the uncertain macroeconomic environment [46][47] Other Important Information - The board of directors declared a $0.30 dividend per share for the quarter ended March 31, 2026, which is expected to be covered over the next 6-12 months [8][32] - The company increased its revolving credit facility to $165 million, with potential to expand to $200 million [9] Q&A Session Summary Question: Market dynamics and investment opportunities - The company noted that market volatility has created a gap in transitional deals, providing opportunities despite uncertainty [21][23] Question: Loan pipeline reduction - Management confirmed that the loan pipeline decreased to $652 million due to a focus on high-quality, actionable deals amidst market volatility [27][28] Question: Foreclosure of the San Antonio asset - The company explained that the Thompson Hotel foreclosure was due to management issues and cash flow constraints, despite the asset being high-quality [29][30] Question: Dividend coverage expectations - Management stated that the board is confident in covering the dividend over the next 6-12 months [32] Question: Capital deployment trends - Management reflected on the evolving opportunity set and the need for selective capital deployment in light of market conditions [44][46]

Summary of Esquire Financial Holdings and Signature Bancorporation Acquisition Conference Call Company and Industry Overview - **Companies Involved**: Esquire Financial Holdings, Inc. (NasdaqCM:ESQ) and Signature Bancorporation, Inc. - **Industry**: Commercial Banking, specifically focusing on litigation financing and middle-market commercial banking Key Transaction Highlights - **Acquisition Announcement**: Esquire Financial Holdings announced the acquisition of Signature Bancorporation on March 12, 2026 [1] - **Strategic Fit**: The acquisition is described as strategically compelling, enhancing scale, resources, and diversifying Esquire's balance sheet [4][6] - **Market Presence**: Signature is positioned in the Chicago market, the third-largest metropolitan area in the U.S., which is seen as a growth engine for both companies [3][4] - **Transaction Structure**: The deal is structured as a 100% common stock transaction with an exchange ratio of 2.63 Esquire shares for each Signature share, valuing Signature at approximately $350 million [9][10] Financial Implications - **Earnings Accretion**: The acquisition is expected to be 23% accretive to Esquire's 2027 earnings per share and 11% accretive to tangible book value [6][24] - **Capital Ratios**: The combined entity will maintain strong capital ratios without raising additional capital [6][25] - **Performance Metrics**: Pro forma metrics post-acquisition include a 2% return on assets (ROA), 18% return on equity (ROE), and a net interest margin (NIM) of 5.25% [22][24] Signature Bancorporation Overview - **Size and Performance**: Signature is a $2 billion bank with $1.3 billion in loans and a strong efficiency ratio of 41% [7][8] - **Deposit Base**: Signature has a non-interest-bearing deposit base of 35% and a cost of funds of 1.42% [8][23] - **Growth Rate**: Signature has demonstrated a compounded annual growth rate of 13% over recent years [8] Strategic Rationale - **Market Opportunity**: The Chicago market is highlighted as underserved by Esquire, presenting significant growth potential, particularly in the litigation vertical [19][20][70] - **Complementary Strengths**: The merger combines Esquire's focus on litigation financing with Signature's strong commercial banking capabilities, allowing for cross-learning and enhanced service offerings [65][70] - **Management Team**: The deal retains key executives from Signature, ensuring continuity and leveraging their local market expertise [10][11] Risks and Considerations - **Loan Portfolio**: The acquisition includes four Schedule A loans totaling $70 million, which are criticized but secured by strong collateral [11][37][66] - **Integration Challenges**: The successful integration of the two companies' cultures and operations is crucial for realizing projected synergies and growth [55] Conclusion - **Future Outlook**: The combined entity is expected to create a premier national banking franchise with enhanced liquidity and value creation opportunities for shareholders [75][76] - **Commitment to Growth**: Both companies are committed to leveraging their combined strengths to accelerate growth in the Chicago market and beyond [70][71]

Financial Data and Key Metrics Changes - Consolidated net revenue for Q4 2025 was approximately $97.8 million, down 16.5% year-over-year [9] - Adjusted EBITDA for the fourth quarter was $15.6 million, a decrease of 41.8% [15] - Net loss for Q4 2025 was approximately $54.4 million or $12.24 per share, compared to a net loss of $35.7 million or $7.81 per share for Q4 2024 [21][22] Business Line Data and Key Metrics Changes - Net revenue for the radio broadcasting segment was $35.1 million, a decrease of 26.5% year-over-year [9] - Reach Media segment net revenue was $13.8 million, up 43.9% from the prior year, primarily due to event revenue from the Fantastic Voyage cruise [11] - Digital segment net revenue was down 19.6% to $14.7 million, driven by decreased direct revenue streams [12] - Cable television segment revenue was approximately $34.9 million, a decrease of 16.8%, with advertising revenue down 21.8% [12] Market Data and Key Metrics Changes - Local ad sales were down 19% against markets that were down 12.6%, while national ad sales were down 40.1% against a market decline of 29.2% [9] - Cable subscribers for TV One decreased to 30.2 million from 34.1 million at the end of Q3 [12] Company Strategy and Development Direction - The company is focused on deleveraging its business and taking advantage of offensive opportunities, particularly in the deregulated radio business [6][7] - A significant capital markets transaction was completed, repurchasing a substantial amount of 2028 notes at a discount and extending maturities to 2031 [6][16] Management's Comments on Operating Environment and Future Outlook - The first quarter of 2026 started slower than expected, with current radio pacings down about 5% [5] - Management remains positive about operational changes and upcoming political events that may impact revenue [5] Other Important Information - The company completed a reverse stock split of 1-for-10 in January 2026 to regain compliance with Nasdaq listing requirements [22] - Capital expenditures for the quarter were approximately $3.2 million and $10.1 million for the year [21] Q&A Session Summary - There were no questions during the Q&A session [23]

Financial Data and Key Metrics Changes - In Q4 2025, the company generated net revenues of $6.6 million and EBITDA of $1.5 million, reflecting a decline compared to the same period last year due to a reduction in fleet and softer market conditions [3][12] - For the full year 2025, net revenue totaled $37.8 million, adjusted EBITDA was $12.9 million, and the net loss reached $6.2 million [12] - Daily operating expenses were successfully reduced to approximately $6,300 per day [13] Business Line Data and Key Metrics Changes - The company executed strategic initiatives to enhance earnings, including divesting lower-returning assets and redeploying proceeds into higher-earning Capesize exposure [4] - The fleet utilization remained high at 97.6%, and the fourth quarter TCE was $14,129, consistent with the same period in 2024 [6] Market Data and Key Metrics Changes - The Baltic Kamsarmax Index averaged about $14,800 in early 2026, up from $9,600 during the same period in 2025, while the Baltic Capesize Index averaged about $23,000, compared to $13,000 for the same period last year [8] - The Panamax market showed strong growth in grain and minor bulk ton-miles, while coal trade has moderated [9] Company Strategy and Development Direction - The company aims to transform into a strong cash flow engine, with a disciplined capital allocation approach and a focus on profitable investments [18][19] - The strategy includes acquiring Capesize vessels under profitable time charters and maintaining a balanced commercial strategy between index-linked exposure and fixed rates [7][8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustaining competitive distributions while pursuing growth opportunities, citing strong fundamentals in the Panamax market and improved market conditions [4][7] - The geopolitical crisis in the Middle East adds uncertainty, but management expects increased coal trade flows to offset reduced cargo demand from the Arabian Gulf [9][25] Other Important Information - The company declared its thirteenth consecutive quarterly dividend, reflecting a commitment to capital returns, with cumulative cash dividends of approximately $1.84 per share since the program's initiation [3][18] - The company has engaged in extensive share repurchases as part of its capital returns options [18] Q&A Session Summary Question: Dividend policy and future payouts - Management intends to establish a clear formula for dividends, emphasizing a commitment to generous shareholder returns [21][22] Question: Acquisition details of the Squireship - The fixed rate for the Squireship is approximately $28,000, with a strategy to finance the acquisition at a leverage ratio of around 60%-65% [23] Question: Implications of coal trade flows - Management expects increased coal trades due to disruptions in LNG trade, particularly in the context of rising electrification needs [24][25] Question: Fleet presence in the Gulf area - Management noted that about 2% of the global fleet is in the Gulf area, which could impact market dynamics [26]

Financial Data and Key Metrics Changes - SNDL achieved record full-year net revenue of CAD 946 million, representing a growth of 2.8% year-over-year, supported by 11% growth from combined cannabis segments, partially offset by a 2.8% decline in liquor [10] - Free cash flow for 2025 reached CAD 18 million, more than doubling the result from the previous year [3][11] - Gross profit for Q4 was CAD 70.2 million, marking a new quarterly record, with a gross margin increase of 110 basis points to 27.8% [9] Business Line Data and Key Metrics Changes - The cannabis retail segment achieved a full-year revenue record of CAD 330 million, representing a 6% growth, supported by same-store sales growth of 3.9% and new store openings [19] - The liquor segment experienced a 2% year-over-year decline in net revenue for Q4, but managed to maintain or expand gross profit through productivity improvements [13][17] - Cannabis operations delivered record net revenue of CAD 144.7 million for the full year, representing a growth of 32%, supported by the Indiva acquisition [20] Market Data and Key Metrics Changes - Both retail and operations segments gained market share despite a market slowdown in the second half of 2025 [4] - The liquor segment faced a consistent revenue decline of approximately 3% year-over-year, driven by broader market conditions [17][43] - The cannabis market experienced a slowdown in the second half of 2025, leading to a decline in the fourth quarter [12][30] Company Strategy and Development Direction - SNDL is focused on growth, profitability, and people, with plans to continue expanding its market share through new store openings and strategic acquisitions [22][24] - The company aims to leverage its strong balance sheet with no debt and over CAD 250 million in unrestricted cash for disciplined capital deployment [5] - SNDL is positioned to capitalize on industry consolidation opportunities as less efficient operators face increased pressure [12][34] Management's Comments on Operating Environment and Future Outlook - Management noted that the market is becoming saturated, particularly in retail, leading to declines in traffic and top-line revenue [30] - The company remains committed to sustaining its upward trajectory in profitability despite market headwinds [12] - Management expressed optimism about the potential for international growth and the completion of EU GMP certification by summer [39] Other Important Information - SNDL has repurchased a total of 15.1 million shares since Q4 2024, including 4.3 million shares in the last 90 days [7] - The company is finalizing the acquisition of Cost Cannabis retail stores, incorporating five locations in Alberta and Saskatchewan [5][32] Q&A Session Summary Question: What is behind the slowdown in the SNDL retail segment? - Management attributed the slowdown to market saturation, competitive pressures, and a shift in focus towards profitability and mix improvements [30] Question: When is the acquisition of 1CM Inc. stores expected to close? - Management expects to report back to shareholders on the timing in Q2, as they are finalizing their review with the AGCO [33] Question: How does SNDL view the liquor retail market outlook for 2026? - Management indicated that while there are structural challenges, certain areas within their portfolio, like the Wine and Beyond banner, are showing strength and growth [44] Question: What is the status of EU GMP certification and international growth outlook? - Management expects to complete the EU GMP certification by summer and anticipates material growth in international business, albeit from a small base [39] Question: What is the current status of the U.S. assets, particularly Parallel and Skymint? - Management noted that they are nearing resolution on the foreclosure process for Parallel and expect to finalize it in Q2 [50]